ug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as hig

ug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as hig

body", "text":"Ronny Gal, a securities analyst at Sanford C. Bernstein & Company who follows the pharmaceutical industry, s

is a Managing Director, Equity Research. covering Financial Technology stocks at Wedbush Securities. He joined Wedbush in 2005 and was previously at Sanford C. Bernstein covering large U.S. telecommunications companies. Prior to that he was a Manager with Deloitte Consulting focused on telecommunications companies.

g more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as h

4, 20] 0 Meet= name: Account # : May 4 21J1U 1 j: jb GHISLA1PIE MAXWELL Ghislaine. Maxwell P Bank. Name: JPMorgan Chase Bank Account Name: Sanford C. Bernstein (St ABA Routing #: Account #: To further credit the account of Bernstein Account Name: GINSLAINE MAXWELL Bernstein Account #: EFTA01589028 14

romoted to Public Investment Director in 2012. Prior to joining New Leaf, Isaac was an Associate in the Global Biotechnology Equity Research group at Sanford C. Bernstein. Previously, Isaac worked as an Associate in the Biotechnology Equity Research group at Deutsche Bank and was a Senior Analyst at Health Advances, a